Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies

Journal of Hypertension

Volumn 35, Issue 3, 2017, Pages 493-500

  Bonnet, Fabrice ^a,b,c   Gastaldelli, Amalia ^d   Pihan Le Bars, Florence ^a   Natali, Andrea ^e   Roussel, Ronan ^f,g   Petrie, John ^h   Tichet, Jean ⁱ   Marre, Michel ^d   Fromenty, Bernard ^j   Balkau, Beverley ^b,c  

^a UNIVERSITÉ DE RENNES 1   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CNR   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g BICHAT HOSPITAL   (France)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ Institut inter Régional Pour la Santé   (France)

^j INSERM   (France)

more..

Author keywords

Alanine transaminase; Fatty liver; Gamma glutamyltransferase; Humans; Hypertension; Incidence; Insulin resistance; Longitudinal studies

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; FATTY LIVER; FEMALE; FOLLOW UP; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; SMOKING HABIT; WAIST CIRCUMFERENCE; BIOSYNTHESIS; BLOOD; BODY MASS; COMPLICATION; DIET RESTRICTION; INCIDENCE; MIDDLE AGED;

ADULT; ALANINE TRANSAMINASE; BLOOD GLUCOSE; BODY MASS INDEX; FASTING; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; HYPERTENSION; INCIDENCE; INSULIN; INSULIN RESISTANCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 85006323727     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001204     Document Type: Article

References (41)

1. Imhof A, Kratzer W, Boehm B, Meitinger K, Trischler G, Steinbach G, et al. Prevalence of nonalcoholic fatty liver and characteristics in overweight adolescents in the general population. Eur J Epidemiol 2007; 22:889-897.
2. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98:483-495.
3. EASL-EASD-EASO. EASL-EASD-EASO clinical practice guidelines for the management of nonalcoholic fatty liver disease. J Hepatol 2016; 64:1388-1402.
4. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6:33.
5. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F, Group Study DESIR. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S. I. R. study. BMC Gastroenterol 2010; 10:56.
6. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21:732-737.
7. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32:741-750.
8. 2: the role of gamma-glutamyltransferase. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetologia 2010; 53:247-253.
9. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007; 27:2729-2735.
10. Wannamethee SG, Lennon L, Shaper AG. The value of gamma-gluta-myltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008; 201:168-175.
11. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-1350.
12. Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis 2014; 236:7-17.
13. Huang RC, Beilin LJ, Ayonrinde O, Mori TA, Olynyk JK, Burrows S, et al. Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents. Hepatology 2013; 58:1306-1314.
14. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol 2014; 60:1040-1045.
15. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012; 380:601-610.
16. Petrie JR, Malik MO, Balkau B, Perry CG, Hojlund K, Pataky Z, et al. Euglycemic clamp insulin sensitivity and longitudinal systolic blood pressure: role of sex. Hypertension 2013; 62:404-409.
17. Bonnet F, Ducluzeau PH, Gastaldelli A, Laville M, Anderwald CH, Konrad T, et al. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes 2011; 60:1660-1667.
18. Bonnet F, Roussel R, Natali A, Cauchi S, Petrie J, Laville M, et al. Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts. Diabetologia 2013; 56:2414-2423.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
20. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49:1537-1544.
21. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, et al. The EGIR-RISC Study (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 2004; 47: 566-570.
22. Bonnet F, Patel S, Laville M, Balkau B, Favuzzi A, Monti LD, et al. Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. Diabetes Care 2008; 31:789-794.
23. Abdul-Ghani MA, Matsuda M, Balas B, De Fronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007; 30:89-94.
24. Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis 2015; 238:356-364.
25. Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012; 55:1406-1415.
26. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004; 38:535-539.
27. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44:248-252.
28. Eslami S, Sahebkar A. Glutathione-S-transferase M1 and T1 null genotypes are associated with hypertension risk: a systematic review and meta-analysis of 12 studies. Curr Hypertens Rep 2014; 16:432.
29. Mansego ML, Solar Gde M, Alonso MP, Martinez F, Saez GT, Escudero JC, et al. Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens 2011; 29:492-500.
30. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010; 52: 1156-1161.
31. Lopez-Suarez A, Guerrero JM, Elvira-Gonzalez J, Beltran-Robles M, Canas-Hormigo F, Bascunana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol 2011; 23:1011-1017.
32. Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens 2015; 33:1207-1214.
33. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between nonalcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol 2014; 29:1926-1931.
34. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28:2913-2918.
35. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350-357.
36. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008; 7:125-134.
37. Kathirvel E, Morgan K, Nandgiri G, Sandoval BC, Caudill MA, Bottiglieri T, et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol 2010; 299:G1068-G1077.
38. Dong Y, Gao G, Fan H, Li S, Li X, Liu W. Activation of the liver X receptor by agonist TO901317 improves hepatic insulin resistance via suppressing reactive oxygen species and JNK pathway. PLoS One 2015; 10:e0124778.
39. Gutierrez J, Ballinger SW, Darley-Usmar VM, Landar A. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res 2006; 99:924-932.
40. Bjornholt JV, Erikssen G, Kjeldsen SE, Bodegard J, Thaulow E, Erikssen J. Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure. J Hypertens 2003; 21:1383-1389.
41. Bower JK, Appel LJ, Matsushita K, Young JH, Alonso A, Brancati FL, et al. Glycated hemoglobin and risk of hypertension in the atherosclerosis risk in communities study. Diabetes Care 2012; 35:1031-1037.